It's not a heavily trafficked company. These things happen. Stick with the event: here's what you know for sure... The company, in the 10-k that was maligned above for some reason, said that manufacturing was deemed acceptable by the FDA. This was a big deal as it had caused a prior delay on the drug. They had an SPA and met the efficacy endpoints and showed a favorable toxicity profile versus other drugs in this space. So what's left? Why get frightened because of animal spirits? Do your work, lots of drugs trade sideways or down in front of FDA and get approved. We had a fun example with Clinical Data just a few weeks back.
Investors are responding to the disclosures in the 10K. Very unusual way to put out an annual 10K. No press release, no conference call. Just posted to SEC afterhours with no notification. You have to ask yourself, can you trust this company?